Zymo Research

Executive Summary

Zymo Research is a privately held biomedical company based in Irvine, California, founded in 1994. Specializing in epigenetics, next-generation sequencing (NGS), and microbiome research, the company provides a comprehensive suite of products and services that enable scientists in academia and industry to advance their discoveries. Zymo's portfolio includes DNA/RNA purification kits, bisulfite conversion kits for methylation analysis, NGS library preparation tools, and microbiome sampling and stabilization solutions. The company has established a strong reputation for innovation and quality, with products cited in thousands of peer-reviewed publications. While serving the research market, Zymo is also expanding into diagnostics, leveraging its expertise in epigenetic biomarkers and microbiome analysis for clinical applications. As a private entity, financial details are scarce, but the company's sustained presence for over three decades and global distribution network underscore its stability and market relevance. The lack of disclosed funding rounds suggests it remains self-funded or revenues supported. With ongoing trends in precision medicine and microbiome therapeutics, Zymo is well-positioned to capture growth, though competition from larger players like Illumina and Qiagen remains a challenge.

Upcoming Catalysts (preview)

• Q3 2026Launch of a direct-to-consumer epigenetic age test70% success
• TBDFDA clearance for a microbiome-based diagnostic for colorectal cancer50% success
• Q4 2026Strategic partnership with a major pharmaceutical company for epigenetic biomarker discovery65% success